Chongqing Zhifei Biological Products (300122.SZ): Mid-term profit distribution of 10 shares for every 2 yuan in 2024. The equity registration date is December 24.

On December 17, Gelonghui announced that Chongqing Zhifei Biological Products (300122.SZ) has released its mid-term equity distribution plan for 2024: based on the company's total share capital of 2,393,789,747 shares, a cash distribution of 2.000000 yuan per 10 shares (tax included) will be made to all Shareholders. The record date for this equity distribution is December 24, 2024, and the ex-rights and ex-dividend date is December 25, 2024.

Gelonghui FinanceDec 17 07:41 ET

Chongqing Zhifei Biological Products (300122.SZ) intends to distribute 2 yuan for every 10 shares, with the ex-rights and ex-dividend date on December 25.

Chongqing Zhifei Biological Products (300122.SZ) announced that the proposed distribution of equity for the mid-term in 2024 is: to distribute to all Shareholders every 10...

Zhitong FinanceDec 17 07:20 ET

Chongqing Zhifei Biological Products (SZSE:300122) Earnings and Shareholder Returns Have Been Trending Downwards for the Last Three Years, but the Stock Advances 4.4% This Past Week

Simply Wall StDec 11 21:52 ET

Chongqing Zhifei Biological, GSK Adjust Terms of Cooperation Agreement

MT NewswiresDec 9 00:27 ET

Chongqing Zhifei Biological Products (300122.SZ): Optimized and adjusted strategic cooperation with GSK, the forecasted procurement amount for the restructuring of the shingles vaccine is approximately 21.6 billion yuan.

GeLonghui December 5th丨 Chongqing Zhifei Biological Products (300122.SZ) announced that the company has signed a "Exclusive Distribution and Joint Promotion Agreement Supplementary Agreement" with GlaxoSmithKline Biologicals and GlaxoSmithKline Hong Kong (collectively referred to as "GSK"), optimizing and adjusting the relevant terms of the original "Exclusive Distribution and Joint Promotion Agreement" signed on October 8, 2023 for the restructuring of the Herpes Zoster vaccine procurement plan, and further expanding the company's exclusive import, distribution, and co-promotion rights period for the recombinant Herpes Zoster vaccine in mainland China. In addition, the supplementary agreement further clarifies that the company will exclusively explore and integrate with GSK.

Gelonghui FinanceDec 5 05:15 ET

Express News | Chongqing Zhifei Biological Products Says Co Will Work With GSK in Commercialization of Rsv Vaccines in China

ReutersDec 5 05:07 ET